A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

Table 2 Incidence of drug-related adverse events

* Only side effects, which have occured in more than 5% of the patients are listed
† Any grade 3 adverse event has been listed

ISSN: 1471-2407